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MaBACKGROUND Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C) using a statin is
associated with signiﬁcant reduction in cardiovascular events. Whether visit-to-visit variability in LDL-C levels affects
cardiovascular outcomes is unknown.
OBJECTIVES This study sought to evaluate the role of visit-to-visit variability in LDL-C levels on cardiovascular
outcomes.
METHODS Weevaluatedpatientswith coronary artery disease andLDL-C<130mg/dl enrolled in theTNT (Treating toNew
Targets) trial, randomly assigned to receive atorvastatin 80 mg/day versus 10 mg/day and with at least one post-baseline
measurement of LDL-C. Visit-to-visit LDL-C variability was evaluated from 3 months into random assignment through the
use of various measurements of LDL-C variability: SD, average successive variability (ASV), coefﬁcient of variation, and
variation independent ofmean, with the ﬁrst 2measurements used as the primarymeasurements. Primary outcomewas any
coronary event, and secondary outcomes were any cardiovascular event, death, myocardial infarction, or stroke.
RESULTS Among 9,572 patients, SD and ASV were signiﬁcantly lower with atorvastatin 80 mg/day versus 10 mg/day
(SD: 12.03  9.70 vs. 12.52  7.43; p ¼ 0.005; ASV: 12.84  10.48 vs. 13.76  8.69; p < 0.0001). In the adjusted model,
each 1-SD increase in LDL-C variability (by ASV) increased the risk of any coronary event by 16% (hazard ratio [HR]: 1.16;
95% conﬁdence interval [CI]: 1.10 to 1.23; p < 0.0001), any cardiovascular event by 11% (HR: 1.11; 95% CI: 1.07 to 1.15;
p < 0.0001), death by 23% (HR: 1.23; 95% CI: 1.14 to 1.34; p < 0.0001), myocardial infarction by 10% (HR: 1.10; 95% CI:
1.02 to 1.19; p ¼ 0.02), and stroke by 17% (HR: 1.17; 95% CI: 1.04 to 1.31; p ¼ 0.01), independent of treatment effect and
achieved LDL-C levels. Results were largely consistent when adjusted for medication adherence.
CONCLUSIONS In subjects with coronary artery disease, visit-to-visit LDL-C variability is an independent predictor of
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ABBR EV I A T I ON S
AND ACRONYMS
ASV = average successive
variability
CAD = coronary artery disease
CV = coefﬁcient of variation
HR = hazard ratio
LDL-C = low-density
lipoprotein cholesterol
MI = myocardial infarction
VIM = variation independent
of mean
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1540guidelines have strongly recommended statin
therapy for patients at risk of cardiovascular
events and in patients after a coronary event
(7,8). In addition, a signiﬁcant reduction in
major vascular events has been shown with
more intensive statin therapywhen compared
with less intensive statin therapy (1,2). In
the TNT (Treating to New Targets) trial, in-
tensive statin therapy with atorvastatin
80 mg/day reduced major cardiovascular
events by 22% when compared with standard
statin therapy with atorvastatin 10 mg/day
(2). Although intensive statin therapy reducedthe risk of cardiovascular events in TNT, there still re-
mains a residual risk of cardiovascular events in the
intensive statin therapy group.SEE PAGE 1549Visit-to-visit variability in blood pressure has been
shown to predict the risk of adverse long-term car-
diovascular outcomes including stroke in patients
with hypertension, independent of achieved systolic
pressure. This suggests a preference for more uni-
form/less variable blood pressure, despite the natural
diurnal variation in blood pressure (9–11). Although
statin therapy lowers LDL-C, variability in LDL-C levels
is not uncommon. Whether visit-to-visit variability in
LDL-C affects future cardiovascular outcomes is not
known. Moreover, the question is increasingly impor-
tant for patients receiving intermittent statin therapy,
patients who are noncompliant with therapy, and for
trials with monoclonal antibodies to PCSK-9, because
the LDL-C variability appears to be less with every
2-week dosing compared with every 4-week dosing
with these agents (12). Our objective was to evaluate
the relationship between visit-to-visit variability in
LDL-C and risk of coronary and other cardiovascular
events through the use of data from the TNT trial.
METHODS
PATIENT POPULATION. This is a post-hoc analysis
from the TNT trial which was a double-blind, parallel-
group study in patients 35 to 75 years of age who
had known CAD (deﬁned by one or more of the
following: previous myocardial infarction [MI], pre-
vious or current angina with objective evidence of
CAD, or prior coronary revascularization), with an
LDL-C level <130 mg/dl. Patients were randomly
assigned 1:1 to atorvastatin 80 mg/day versus
10 mg/day. The design and the principal results have
been described in detail previously (2,13). The TNT
trial is registered on clinicaltrials.gov (NCT00327691).
The institutional review board at each participatingsite approved the trial, and written informed consent
was obtained from each patient.
LDL-C VARIABILITY MEASUREMENTS. For this anal-
ysis, subjects with at least 1 post-baseline LDL-C
measurements were included. Visit-to-visit vari-
ability in achieved LDL-C levels was evaluated
through the use of LDL-C measurements from 3
months onward into random assignment because this
was the period in which the LDL-C levels in the 2
treatment arms were relatively stable after the initial
decrease. Visit-to-visit LDL-C variability was deﬁned
as variability in LDL-C values between visits. For
patients with missing LDL-C values at any visit, any
other available LDL-C data were used to calculate
LDL-C variability. Various measurements of vari-
ability were used: 1) the SD of LDL-C levels; 2) the
average successive variability (ASV), which was
deﬁned as the average absolute difference between
successive values; 3) coefﬁcient of variation (CV); and
4) variability independent of the mean (VIM). VIM was
calculated as 100  SD/Meanbeta, where beta is the
regression coefﬁcient, on the basis of natural loga-
rithm of SD on natural logarithm of mean. In addition,
this uncorrected VIM was corrected by use of the
formula [VIM uncorrected  (mean of CV)]/(mean of
VIM uncorrected). In the TNT trial, the achieved
mean LDL-C was signiﬁcantly lower in the atorvas-
tatin 80 mg/day when compared with atorvastatin
10 mg/day, and, because of this variability, measure-
ments that are less sensitive tomean LDL-C levels such
as SD and ASV were used as the primary analysis and
were preferentially used for data interpretation and
inference, although all 4 measurements are presented.
FOLLOW-UP. Patients were followed up at week 12
and at months 6, 9, and 12 during the ﬁrst year and
then every 6 months thereafter. At each visit, vital
signs, clinical endpoints, adverse events, and con-
current medication information were recorded. In
addition, on alternating visits (i.e., annually), phys-
ical examinations and electrocardiograms were per-
formed and laboratory specimens, including LDL-C
cholesterol measurements, were collected.
STUDY OUTCOMES. The primary outcome for this
analysis was the occurrence of any coronary event
deﬁned as coronary heart disease death, non-fatal MI,
resuscitated cardiac arrest, revascularization or
angina. The secondary outcomes were any cardio-
vascular event (any coronary event or cerebrovascu-
lar event, peripheral vascular disease, heart failure),
death, MI, or stroke (2).
STATISTICAL ANALYSIS. The Cox proportional haz-
ards regression model was used to evaluate the
CENTRAL ILLUSTRATION Visit-to-Visit LDL-C Variability and Outcomes
Visit-to-visit LDL-C variability was deﬁned as variability in LDL-C values between visits, on the basis of 9,572 patients from the TNT trial. LDL-C variability
measured from 3 months onward into random assignment because this was the relatively steady phase in LDL-C after the initial decrease. CV ¼ cardio-
vascular; LDL-C ¼ low-density lipoprotein cholesterol; MI ¼ myocardial infarction.
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1541relationship between LDL-C variability measure-
ments and the risk of primary and secondary out-
comes for the overall cohort. Three different models
were used to calculate the hazard ratio (HR) for pri-
mary and secondary outcomes per 1-SD increase of
variability in LDL-C: model 1 was the unadjusted
model with LDL-C variability used as a continuous
variable; model 2 adjusted model 1 for treatment ef-
fect (atorvastatin 80 mg/day vs. 10 mg/day); and
model 3 adjusted model 2 to mean LDL-C values
(continuous). Analyses were also performed to eval-
uate the above relationship for the 2 randomized
groups separately, and the interaction between
treatment and LDL-C variability parameter groups
was on the basis of the Wald test of the interaction
from a Cox proportional hazards model including
treatment, LDL-C variability parameter, and the cor-
responding interaction term in the model. All ana-
lyses were performed with the use of SAS software
version 9.0 (SAS Institute, Cary, North Carolina). A
value of p < 0.05 (2-sided) was considered statisti-
cally signiﬁcant.
SENSITIVITY ANALYSES. A number of analyses were
performed to assess the robustness of the ﬁndings:
1) adjustment for medication adherence: because
LDL-C levels can be heavily inﬂuenced by patient
medication adherence, we performed additional ana-
lyses adjusting for medication adherence (using pill
count) as a time-dependent covariate; 2) restricting
the cohort to those with non-missing LDL-C values atevery visit; 3) use of LDL-C variability measurement as
a time-dependent covariate to assess if the risk varied
with time; and 4) assessment of interaction between
baseline variables and LDL-C variability measurement
and outcomes.
RESULTS
Among the 10,001 patients included in the TNT trial,
9,572 patients with at least 1 post-baseline lipid mea-
surement were included in this analysis. Atorvastatin
80 mg/day was associated with signiﬁcant reduction
in mean LDL-C (–23.7; 95% CI: –24.4 to –23; p < 0.0001)
minimum LDL-C (–22.2; 95% CI: –22.9 to –21.5;
p < 0.0001), and maximum LDL-C (–23.7; 95% CI: –24.7
to –22.7; p < 0.0001] when compared with atorvastatin
10 mg/day. In addition, atorvastatin 80 mg/day was
associated with lower visit-to-visit LDL-C variability
(SD: 12.03  9.70 vs. 12.52  7.43; p ¼ 0.005; ASV: 12.84
 10.48 vs. 13.76  8.69; p < 0.0001) when compared
with atorvastatin 10 mg/day.
VISIT-TO-VISIT LDL-C VARIABILITY AND ANY
CORONARY EVENT. In the unadjusted model, visit-
to-visit LDL-C variability was associated with a sig-
niﬁcant increase in the risk of any coronary event
(Figure 1). For every 1-SD increase in LDL-C, the risk of
any coronary event increased by 13% (HR: 1.13; 95%
CI: 1.07 to 1.20; p < 0.0001). In addition, visit-to-visit
LDL-C as measured by SD LDL-C was an independent
predictor of any coronary event even after controlling







Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
1.13 1.07 1.20 <0.0001
1.14 1.07 1.20 <0.0001
1.10 1.03 1.17 0.005
1.18 1.13 1.24 <0.0001
1.18 1.13 1.24 <0.0001
1.16 1.10 1.23 <0.0001
1.08 1.02 1.15 0.007
1.11 1.05 1.18 0.001
1.09 1.03 1.16 0.004
1.09 1.03 1.16 0.004
1.11 1.05 1.18 0.0004
1.09 1.03 1.16 0.004
LDL-C Variability Adjusted Covariate (s) HR (95% CI) HR 95% CI P-Value
HR (95% CI)
0.50 1.00 1.50
For every 1-SD increase in LDL-C variability, the risk of any coronary event increased in the unadjusted model and models adjusted for treatment
and adjusted for treatment and mean LDL-C levels. ASV ¼ average successive variability; CI ¼ conﬁdence interval; CV ¼ coefﬁcient of variation;
HR ¼ hazard ratio; LDL-C ¼ low-density lipoprotein cholesterol; VIM ¼ variation independent of mean.
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LDL-C levels. A similar relationship was seen with
ASV of LDL-C and also with other measurements of
LDL-C variability and the risk of any coronary event.
Analyses were performed to evaluate the indepen-
dent effect of randomized treatment, LDL-C values,
and visit-to-visit LDL-C variability measurements
(Table 1). When LDL-C variables (mean, minimum, or
maximum) were added to treatment variable, the HR
for treatment effect was no longer signiﬁcant, indi-
cating that the treatment effect is mediated through
reducing the mean, minimum, or maximum LDL-C
levels. However, the treatment effect stayed signiﬁ-
cant after adjusting for LDL-C variability measure-
ments, indicating that the impact of visit-to-visit
LDL-C variability and treatment effect on any coronary
event are independent (Table 1).
VISIT-TO-VISIT LDL-C VARIABILITY AND ANY CARDIO-
VASCULAR EVENT. In the unadjusted model, visit-
to-visit LDL-C variability was associated with
signiﬁcant increase in the risk of any cardiovascular
event (Figure 2). For every 1-SD increase in LDL-C, therisk of any cardiovascular event increased by 8%
(HR: 1.08; 95% CI: 1.04 to 1.12; p < 0.0001). In addi-
tion, visit-to-visit LDL-C as measured by SD LDL-C
was an independent predictor of any cardiovascular
event even after controlling for randomized treat-
ment and mean achieved LDL-C levels. A similar
relationship was seen with ASV of LDL-C and also
with other measurements of LDL-C variability and the
risk of any cardiovascular event.
When LDL-C variables (mean, minimum, or maxi-
mum) were added to treatment variable, the HR for
treatment effect was no longer signiﬁcant, indicating
that the treatment effect is mediated through re-
ducing the mean, minimum, or maximum LDL-C
levels (Table 2). However, the treatment effect
stayed signiﬁcant after adjusting for LDL-C variability
measurements, indicating that the impact of visit-to-
visit LDL-C variability and treatment effect on any
cardiovascular event are independent (Table 2).
VISIT-TO-VISIT LDL-C VARIABILITY AND DEATH. Every
1 SD of ASV of LDL-C was associated with a 17% in-
crease in death (HR: 1.17; 95% CI: 1.08 to 1.25;
TABLE 1 Effects of Randomized Treatment Allocation on the Risk of Any Coronary Events Adjusted for Parameters of LDL-C
(as a Continuous Variable)
Independent Variables
HR for Treatment Effect
HR for 1-SD Increase in
Mean LDL-C
HR for 1-SD Increase in
LDL-C Variability
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Treatment (Rx) 0.80 (0.70–0.91) 0.001 – – – –
LDL-C – –
Rx þ mean LDL-C 0.95 (0.81–1.10) 0.47 1.16 (1.08–1.25) <0.0001 – –
Rx þ minimum LDL-C 0.92 (0.79–1.07) 0.29 1.13 (1.05–1.22) 0.002 – –
Rx þ maximum LDL-C 0.88 (0.76–1.00) 0.06 1.12 (1.05–1.19) 0.001 – –
LDL-C variability
Rx þ SD LDL-C 0.80 (0.70–0.91) 0.001 – – 1.13 (1.07–1.20) <0.0001
Rx þ ASV LDL-C 0.81 (0.71–0.92) 0.001 – – 1.18 (1.13–1.24) <0.0001
Rx þ CV LDL-C 0.77 (0.67–0.88) <0.0001 – – 1.11 (1.04–1.18) 0.001
Rx þ VIM LDL-C 0.77 (0.68–0.88) <0.0001 – – 1.11 (1.05–1.18) 0.0004
Rx þ mean LDL-C þ SD LDL-C 0.89 (0.76–1.04) 0.14 1.10 (1.01–1.20) 0.02 1.10 (1.03–1.17) 0.005
Rx þ mean LDL-C þ ASV LDL-C 0.86 (0.74–1.01) 0.06 1.06 (0.98–1.16) 0.13 1.16 (1.09–1.23) <0.0001
Rx þ mean LDL-C þ CV LDL-C 0.90 (0.77–1.05) 0.17 1.14 (1.06–1.23) 0.0004 1.09 (1.03–1.16) 0.004
Rx þ mean LDL-C þ VIM LDL-C 0.90 (0.77–1.05) 0.17 1.14 (1.06–1.23) 0.001 1.09 (1.03–1.16) 0.004
Values are HR and 95% conﬁdence intervals and their corresponding p Values.
ASV ¼ average successive variability; CI ¼ conﬁdence interval; CV ¼ coefﬁcient of variation; HR ¼ hazard ratio; LDL-C ¼ low-density lipoprotein cholesterol; VIM ¼ variation
independent of mean.







Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
1.08 1.04 1.12 <0.0001
1.08 1.04 1.12 <0.0001
1.08 1.04 1.12 0.0001
1.10 1.07 1.14 <0.0001
1.10 1.07 1.14 <0.0001
1.11 1.07 1.15 <0.0001
1.06 1.02 1.09 0.002
1.08 1.04 1.12 <0.0001
1.07 1.04 1.11 <0.0001
1.06 1.02 1.10 0.001
1.08 1.04 1.12 <0.0001
1.07 1.04 1.11 <0.0001
LDL-C Variability Adjusted Covariate (s) HR (95% CI) HR 95% CI P-Value
HR (95% CI)
0.50 1.00 1.50
For every 1-SD increase in LDL-C variability, the risk of any cardiovascular event increased in the unadjusted model and models adjusted for
treatment and adjusted for treatment and mean LDL-C levels. Abbreviations as in Figure 1.
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TABLE 2 Effects of Randomized Treatment Allocation on the Risk of Any Cardiovascular Events Adjusted for Parameters of LDL-C
(as a Continuous Variable)
Independent Variables
HR for Treatment Effect
HR for 1-SD Increase in
Mean LDL-C
HR for 1-SD Increase in
LDL-C Variability
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Treatment (Rx) 0.77 (0.60–0.98) 0.04 – – – –
LDL-C
Rx þ mean LDL-C 0.75 (0.56–1.01) 0.06 0.98 (0.85–1.14) 0.81 – –
Rx þ minimum LDL-C 0.77 (0.57–1.04) 0.09 1.00 (0.86–1.16) 0.98 – –
Rx þ maximum LDL-C 0.79 (0.60–1.03) 0.08 1.03 (0.90–1.17) 0.69 – –
LDL-C variability
Rx þ SD LDL-C 0.77 (0.60–0.99) 0.04 – – 1.10 (0.99–1.23) 0.08
Rx þ ASV LDL-C 0.78 (0.61–0.99) 0.04 – – 1.13 (1.02–1.25) 0.02
Rx þ CV LDL-C 0.74 (0.58–0.95) 0.02 – – 1.10 (0.98–1.24) 0.10
Rx þ VIM LDL-C 0.74 (0.58–0.95) 0.02 – – 1.10 (0.98–1.24) 0.09
Rx þ mean LDL-C þ SD LDL-C 0.70 (0.52–0.95) 0.02 0.91 (0.78–1.08) 0.29 1.14 (1.00–1.29) 0.04
Rx þ mean LDL-C þ ASV LDL-C 0.70 (0.51–0.94) 0.02 0.90 (0.77–1.06) 0.22 1.17 (1.04–1.31) 0.01
Rx þ mean LDL-C þ CV LDL-C 0.71 (0.53–0.97) 0.03 0.97 (0.83–1.12) 0.67 1.11 (0.98–1.24) 0.09
Rx þ mean LDL-C þ VIM LDL-C 0.71 (0.53–0.97) 0.03 0.96 (0.83–1.12) 0.63 1.11 (0.99–1.24) 0.08
Values are HR and 95% conﬁdence intervals and their corresponding p Values.
Abbreviations as in Table 1.
Bangalore et al. J A C C V O L . 6 5 , N O . 1 5 , 2 0 1 5
LDL-C Variability and Outcomes A P R I L 2 1 , 2 0 1 5 : 1 5 3 9 – 4 8
1544p < 0.0001) in an unadjusted model and a 23% in-
crease in death-independent-of-treatment effect and
achieved LDL-C levels in the adjusted model. Results
were similar for SD of LDL-C, although this did not
reach statistical signiﬁcance (adjusted HR: 1.06; 95%
CI: 0.96–1.17; p ¼ 0.23).
VISIT-TO-VISIT LDL-C VARIABILITY AND MYOCARDIAL
INFARCTION. Every 1 SD of ASV of LDL-C was associ-
ated with a 14% increase inMI (HR: 1.14; 95% CI: 1.06 to
1.23; p ¼ 0.0002) in the unadjusted model (Figure 3)
and a 10% increase in MI independent of treatment
effect and achieved LDL-C levels (Figure 3) in the
adjusted model. Results were similar for SD of LDL-C,
although this did not reach statistical signiﬁcance
(adjusted HR: 1.07; 95% CI: 0.98 to 1.17; p ¼ 0.13).
VISIT-TO-VISIT LDL-C VARIABILITY AND STROKE. Every
1 SD of ASV of LDL-C was associated with a 13%
increase in stroke (HR: 1.13; 95% CI: 1.02 to 1.25;
p ¼ 0.02) in the unadjusted model (Figure 4) and a
17% increase in stroke independent of treatment
effect and achieved LDL-C levels (Figure 3) in the
adjusted model. Results were similar for SD of LDL-C
(adjusted HR: 1.14; 95% CI: 1.01 to 1.29; p ¼ 0.04).
There was no signiﬁcant interaction between
LDL-C variability measurements and treatment effect
for the above clinical outcomes, such that the rela-
tionship was similar for atorvastatin 10 mg/day versus
80 mg/day groups (Online Tables 1 to 4).
SENSITIVITY ANALYSES. The results were similar
in a sensitivity analysis adjusting for treatment
adherence (included as a time-dependent covariate)(Online Table 5). Every 1-SD increase of ASV of LDL-C
was associated with a 17% increase in any coronary
event, 10% increase in any cardiovascular event, 13%
increase in non-fatal MI, and 13% increase in stroke
(Online Table 5), even after controlling for medication
adherence. Similarly, the results were largely consis-
tent in the sensitivity analyses restricted to the cohort
without missing LDL-C values at any scheduled visit
(Online Table 6) and in the analyses that used LDL-C
variability as a time-dependent covariate (Online
Table 7). The test for interaction of select baseline
characteristics was largely non-signiﬁcant (except for
hypertension and the outcome of stroke) (Online
Table 8).
DISCUSSION
The results of this study indicate that visit-to-visit
LDL-C variability is a powerful and independent
predictor of any coronary event, any cardiovascular
event, death, MI, and stroke, independent of treat-
ment effect and achieved LDL-C levels (Central
Illustration). In the adjusted model, each 1-SD in-
crease in LDL-C variability (as measured by ASV)
increased the risk of any coronary event by 16%,
any cardiovascular event by 11%, death by 23%, MI
by 10%, and stroke by 17%, independent of statin
dose and achieved LDL-C levels. The association
was signiﬁcant even after controlling for treatment
adherence.
STATINS AND CARDIOVASCULAR OUTCOMES. Rando-
mized trials, observational studies, andmeta-analyses







Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
1.12 1.04 1.21 0.003
1.12 1.04 1.21 0.004
1.07 0.98 1.17 0.13
1.14 1.06 1.23 0.0002
1.14 1.06 1.23 0.0003
1.10 1.02 1.19 0.02
1.06 0.98 1.15 0.15
1.09 1.00 1.18 0.05
1.07 0.98 1.16 0.13
1.07 0.99 1.16 0.11
1.09 1.01 1.18 0.04
1.07 0.98 1.16 0.12
LDL-C Variability Adjusted Covariate (s) HR (95% CI) HR 95% CI P-Value
HR (95% CI)
0.50 1.00 1.50
For every 1-SD increase in LDL-C variability, the risk of MI increased in the unadjusted model and models adjusted for treatment and adjusted
for treatment and mean LDL-C levels. Abbreviations as in Figure 1.
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1545have shown a signiﬁcant beneﬁt of statins for primary
prevention of cardiovascular events as well as for
secondary prevention (1–4). The results from these
studies indicate that lowering of LDL-C by 1 mmol/l
(approximately 39 mg/dl) with a statin reduces
the incidence of major vascular events by approxi-
mately 20% (4). The standard statin regimen reduces
LDL-C by approximately 30%, with more intensive
statin regiment reducing this level by approximately
50% (4). In addition to a reduction in LDL-C,
other pleotropic effects such as anti-inﬂammatory
properties, plaque stabilization, and others appear
to contribute to the signiﬁcant beneﬁt of statin
therapy. It is therefore not surprising that statins are
the mainstay for prevention and treatment of patients
with CAD and are endorsed by major national
and international guidelines (7,8). Despite this, there
remains a residual risk of cardiovascular events even
in patients receiving an intensive statin regimen.
In the TNT trial, although intensive statin treat-
ment with atorvastatin 80 mg/day reduced cardio-
vascular events when compared with atorvastatin
10 mg/day, the residual risk of major cardiovascularevents was 8.7%, death was 5.7%, MI was 4.9%, and
stroke was 2.3% (2).
Visit-to-visit variability in blood pressure is an
independent predictor of adverse cardiovascular
events, which suggests that a more uniform/less
variable blood pressure is desirable (10). This is true
despite that fact that there is variability in blood
pressure measurement with time of day and with
stress, activity, and emotions. However, it is not
known if the same is applicable to LDL-C control. In
the present study, we measured variability in the
LDL-C levels from 3 months after the initial decrease
onward into random assignment because this was the
period in which the LDL-C levels in the 2 treatment
arms were relatively stable. The results of the present
study indicate a strong and independent effect of
visit-to-visit variability measurements on long-term
cardiovascular outcomes. Each 1-SD increase in
visit-to-visit variability in LDL-C was associated with
a signiﬁcant increase in any coronary event, any
cardiovascular event, death, MI, and stroke, and this
was independent of treatment effect and achieved
LDL-C levels, which suggests that a more uniform and







Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
None
Treatment
Treatment + Mean LDL-C
1.10 0.99 1.23 0.08
1.10 0.99 1.23 0.08
1.14 1.01 1.29 0.04
1.13 1.02 1.25 0.02
1.13 1.02 1.25 0.02
1.17 1.04 1.31 0.01
1.07 0.96 1.20 0.21
1.10 0.98 1.24 0.10
1.11 0.99 1.24 0.09
1.08 0.96 1.21 0.19
1.10 0.98 1.24 0.09
1.11 0.99 1.25 0.08
LDL-C Variability Adjusted Covariate (s) HR (95% CI) HR 95% CI P-Value
HR (95% CI)
0.50 1.00 1.50
For every 1-SD increase in LDL-C variability, the risk of stroke increased in the unadjusted model and models adjusted for treatment and
adjusted for treatment and mean LDL-C levels. Abbreviations as in Figure 1.
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1546less variable visit-to-visit LDL-C is important. The
results of the present study also indicate that visit-to-
visit variability in LDL-C was lower with atorvas-
tatin 80 mg/day when compared with atorvastatin
10 mg/day. It therefore lends credence to the Amer-
ican College of Cardiology/American Heart Associa-
tion blood cholesterol guideline recommendation of
moderate- to high-intensity statins in patients with
atherothrombotic vascular disease (7), not only for a
more robust reduction in LDL-C but also for less
variability in LDL-C. Although the dose of statin was
predictive of visit-to-visit LDL-C variability, other
factors such as adherence with medication also play a
role. In an analysis of 782 patients, visit-to-visit
variability in LDL-C was strongly associated with
statin non-adherence (odds ratio: 3.4; 95% CI: 1.7 to
7.1) (14). However, in our analyses, LDL-C variability
was an independent predictor of events even after
controlling for statin non-adherence. In addition,
visit-to-visit LDL-C variability may be important in
patients receiving intermittent statin therapy. Alter-
native dosing schedules such as a few times per week,every other day, or even once per week have been
investigated as methods to reduce myalgias and yet
achieve efﬁcacy in lowering LDL-C. Intermittent
statin therapy, especially with longer-acting agents
such as rosuvastatin or atorvastatin, is used in pa-
tients who are intolerant to daily statin therapy and
has been shown to result in signiﬁcant LDL-C reduc-
tion, although variability was not reported in these
retrospective studies (15–18). The Canadian Working
Group has recommended intermittent therapy for
suspected statin intolerance (19). However, it remains
unknown whether intermittent statin dosage provides
the same cardiovascular protection as does daily
statin therapy (18). The results of the present study are
interesting with regard to monoclonal antibodies to
PCSK-9 because the visit-to-visit variability with
a once–per-month injection could be substantial. In
the LAPLACE-TIMI 57 trial (LDL-C Assessment With
PCSK9 monoclonaL Antibody Inhibition Combined
With Statin therapy-Thrombolysis In Myocardial
Infarction 57), the LDL-C variability was less when
the medication was dosed every 2 weeks rather than
PERSPECTIVES
COMPETENCY IN PATIENT CARE: Greater variability of
serum LDL-C levels between visits is associated with adverse
clinical cardiovascular outcomes.
TRANSLATIONAL OUTLOOK: Further research is needed
to evaluate predictors of variability in serum LDL-C levels and
identify interventions that ameliorate these adverse effects.
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1547every 4weeks (12). However, whether it affects clinical
outcomes must be tested in future trials.
LDL-C VARIABILITY AND ADVERSE OUTCOMES. The
mechanism linking increased LDL-C variability to an
increased risk of cardiovascular events is unknown,
but there are several hypotheses. Statins stabilize
plaque mainly (but not exclusively) by a cholesterol-
dependent mechanism, reducing the cholesterol
content of plaque. Lipid lowering in turn inhibits
inﬂammation and decreases collagenolytic activity
and thrombotic potential. In addition, the cholesterol-
independent action of statins through alterations in
the function of G proteins also contributes to their
anti-inﬂammatory and antithrombotic actions. LDL-C
variability may cause instability at the vascular wall
as a result of variability in lipid efﬂux mechanism (i.e.,
impair the cholesterol-dependent mechanism of pla-
que stabilization) and thus increase the potential for
plaque vulnerability and rupture, thereby increasing
the risk of cardiovascular events. Another potential
mechanism of this increased risk is perhaps that LDL-C
variability is an epiphenomenon of other systemic
conditions that increase cardiovascular risk. It is
possible that patientswith systemic conditions leading
to generalized frailty might have higher variability of
multiple biological parameters and increased risk
caused by several pathologic mechanisms. Finally,
poor adherence to medications may link LDL vari-
ability with increased risk of cardiovascular events.
LDL variabilitywas an independent predictor of events
even after controlling for medication adherence.
However, adherence was measured by means of pill
counts without testing the “taking compliance” (i.e.,
whether a medication was actually taken) by use of
drug levels. Further studies are needed to test this
hypothesis.
STUDY LIMITATIONS. Our data are derived from a
randomized trial in which the visit-to-visit LDL-C
variability probably is less than in real-world patients.
Despite this, LDL-C variability measurements were
strong and independent predictors of cardiovascular
events. We did not have data on other factors that
could result in higher LDL-C variability, including
contents and proximity to the last meal. However, alllipid parameters in the TNT trial were measured in a
fasting state, thus reducing the variability caused by
proximity of the last meal. In addition, the results
were not consistently seen across all measurements
of LDL-C variability, but the results were largely
similar. Moreover, variability measurements that are
less sensitive to mean LDL levels such as SD and ASV
produced largely consistent results.
CONCLUSIONS
In patients enrolled in the TNT trial, visit-to-visit
variability in LDL-C was a strong and independent
predictor of cardiovascular events independent of
treatment effect, achieved LDL-C levels, and statin
adherence. A 1-SD increase in LDL-C variability
increased the risk of any coronary event by 16%,
any cardiovascular event by 11%, death by 23%, MI
by 10%, and stroke by 17% (Central Illustration).
Although yet to be conﬁrmed in future studies, our
results are important, given the increased variability
in LDL-C in recent clinical trials that used monoclonal
antibodies to PCSK-9 with every 4-weeks dosing
versus every 2-weeks dosing (12) and with intermit-
tent statin dosing strategies (19).
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